Yun-Xiang Zhou,Guo-Bin Zhang
Yun-Xiang Zhou
Catheter Ablation and Oral Anticoagulation for Secondary Stroke Prevention in Atrial Fibrillation: The STABLED Randomized Clinical Trial [0.03%]
房颤卒中二级预防的研究：导管消融与口服抗凝的随机临床试验
Kazumi Kimura,Yasuhiro Nishiyama,Yu-Ki Iwasaki et al.
Kazumi Kimura et al.
Importance: Among patients with atrial fibrillation, those with a recent stroke are at significantly higher risk of recurrence than those without. Catheter ablation is expected to reduce the risk of recurrent stroke, hear...
Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial [0.03%]
小剂量锂治疗轻度认知障碍：一项随机临床试验
Ariel G Gildengers,Tamer S Ibrahim,Stewart J Anderson et al.
Ariel G Gildengers et al.
Importance: Lithium deficiency may contribute to Alzheimer disease pathogenesis. No randomized clinical trial has examined lithium's effects on cognition, neuroimaging, and plasma biomarkers in mild cognitive impairment (...
Timing and Location in Minimally Invasive ICH Surgery-Reply [0.03%]
微创ICH手术的时间和地点-回复评论答复文章标题时，可以简化处理，因此中文译文为：微创ICH手术的时间和地点-回复
Adam S Arthur,David J Fiorella
Adam S Arthur
Mary E Woesner
Mary E Woesner
Sex Differences in Amyloid Pathology by Race, Ancestry, and Apolipoprotein E ε4 in an Admixed Autopsy Sample [0.03%]
种族、祖先和载脂蛋白在混合尸检样本中淀粉样蛋白病理的性别差异ε4
Maison Abu Raya,Claudia Kimie Suemoto,Vitor Ribeiro Paes et al.
Maison Abu Raya et al.
Importance: Sex and racial or ancestral disparities in Alzheimer disease remain incompletely understood; autopsy studies that examine amyloid, tau, and genetic factors are scarce. ...
Hui Chen,Marianna Cortese,Mario H Flores-Torres et al.
Hui Chen et al.
Importance: Healthier diets are generally believed to benefit cognitive health; however, the evidence remains inconsistent, and a systematic examination of multiple healthy dietary patterns within the same context is lack...
Association Between GLP-1 RAs and Idiopathic Intracranial Hypertension-Reply [0.03%]
GLP-1受体激动剂与特发性颅内高压的关系——答函
Georgios S Sioutas,John Reavey-Cantwell,Dennis J Rivet nd
Georgios S Sioutas
Josep Dalmau
Josep Dalmau
Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study [0.03%]
介芬平用于治疗多发性硬化症五年的研究：ULTIMATE I和II开放标签延长试验
Bruce A C Cree,Edward Fox,Hans-Peter Hartung et al.
Bruce A C Cree et al.
Importance: In the 2-year Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (ULTIMATE) I and II randomized clinical studies, disease activity was significant...